The article presents data on the efficacy of erlotinib in the treatment of NSCLC in the presence of EGFR gene mutation. Its advantages over chemotherapy in terms of survival, quality of life, and tolerability of treatment, both as monotherapy and in combination with cytostatics and other targeted drug – VEGF inhibitor – Bevacizumab, are shown. A clinical case of EGFR-positive NSCLC and its treatment with erlotinib was considered. Ways of overcoming resistance to treatment are studied. The use of erlotinib should be considered as one of the standard methods of first and subsequent therapy in patients with NSCLC in later stages with confirmed mutations of the EGFR gene.

This article reviews clinical case of epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer and the usage of osimertinib for its treatment. Targeted drugs, EGFR tyrosine kinase inhibitors were approved for the treatment of non-small cell lung cancer more than 15 years ago*. Updated results of the large multicenter randomized FLAURA trial showed that osimertinib, a third-generation irreversible selective epidermal growth factor receptor tyrosine kinase inhibitor, was more effective than first-generation EGFR tyrosine kinase inhibitors, not only in terms of progression-free survival, but in terms of duration of response and overall survival. Furthermore, statistically and clinically significant benefit is achieved without deterioration of tolerance and quality of life. This article presents a clinical case of a woman who has taken part in this clinical trial. In light of the fact that this patient has been one of the first to receive this therapy in Russia, this experience appears to be interesting, because it allows assess the long-term results of the therapy: the achieved response duration is more than 50 months with good tolerance of therapy.

The article describes a clinical case of ALK-positive non-small cell lung cancer and its long-term treatment with a chemotherapy drug pemetrexed as first-line regimen followed by pemetrexed maintenance therapy.